NL-OMON26843已完成不适用
Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomas
Prof.dr. D.J. Richel0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients present with histologically confirmed diagnosis of intracranial recurrent high grade glial tumor (WHO grade IV). Patients may be entered based on local pathology from the original tumor specimen.
- •2. Patients must have evidence of tumor progression following radiation and
- •chemotherapy as measured by MRI (MRI-0 at presentation).
排除标准
- •1. Patients with inability to comply with protocol or study procedures (for example, an inability to swallow tablets).
- •2. Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
研究者
相似试验
尚未招募
2 期
Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomasbrain tumorRecurrent high grade glial tumors10029211NL-OMON30453Academisch Medisch Centrum30
进行中（未招募）
不适用
Bevacizumab in combination with metronomic dose temozolomide in patients with relapsed high grade gliomas - BEvacizumab + TEmozolomide in Relapsed gliomaPatients with a recurrent high grade glioma (after primary treatment)MedDRA version: 9.1Level: LLTClassification code 10018338Term: GliomaEUCTR2007-000488-38-NLAcademic Medical Center
已完成
不适用
AVAstin and Temozolomide Attacking Relapsed gliomaRelapsed gliomaNeoplasmsCancerISRCTN23008679Academic Medical Centre (AMC) (The Netherlands)23
招募中
不适用
A clinical study of Bevacizumab therapy in combination with chemotherapeutic drugs for children with recurrent gliomaJPRN-UMIN000005528Osaka University Graduate School of Medicine12
撤回
2 期
Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung CancerSmall Cell Lung CancerNCT00755157University Hospital of Crete